Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Abbisko Cayman's Net Income for the
six
months ended in Dec. 2025 was HK$-301.8 Mil. Abbisko Cayman's Revenue for the
six
months ended in Dec. 2025 was HK$0.0 Mil. Therefore, Abbisko Cayman's net margin for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Abbisko Cayman's Net Margin % or its related term are showing as below:
HKSE:02256'
s Net Margin % Range Over the Past 10 Years
Min: -7979.97 Med: -1129.38 Max: 9.03
Current: 8.55
HKSE:02256's Net Margin % is ranked better than 79.45% of 944
companies
in the Biotechnology industry
Industry Median: -82.44
vs HKSE:02256: 8.55
Abbisko Cayman (HKSE:02256) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Abbisko Cayman Net Margin % Related Terms
Abbisko Cayman Net Margin % Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02256 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Abbisko Cayman's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Net Margin % distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (HKSE:02256) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Abbisko Cayman and its competitors. According to the industry distribution chart, Abbisko Cayman ranks #194 out of 944 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Abbisko Cayman's Net Margin % too high?
Abbisko Cayman's current Net Margin % is 0.00%. Based on the distribution chart, Abbisko Cayman ranks #194 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #194 out of 944 companies for Net Margin %. This places Abbisko Cayman in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Net Margin % is 0.00%. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30.
GuruFocus considers Abbisko Cayman to be Modestly Undervalued.
Key valuation signals for HKSE:02256:
Net Margin %: 0.00%
GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score
Get the complete analysis for HKSE:02256
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02256 has been successfully added to your 
